Thrombopoietin: Physiology and What Research Reports

What Thrombopoietin Is

Thrombopoietin, usually abbreviated TPO and also referred to by the gene name THPO, is a glycoprotein hormone that acts as the principal regulator of megakaryocyte development and platelet production. It belongs to the same broad structural family as erythropoietin and other haematopoietic cytokines: an N-terminal receptor-binding domain that engages its receptor, and a heavily glycosylated C-terminal region that influences circulating half-life. Its receptor is MPL (also called the thrombopoietin receptor or c-Mpl), a single-pass cytokine receptor expressed on megakaryocytes, platelets and haematopoietic stem and progenitor cells.

Because TPO sits at the top of the platelet production pathway, it appears in three quite different literatures at once: basic haematopoiesis research, clinical haematology (where low platelet counts are the problem being managed), and receptor-pharmacology work on molecules designed to engage MPL. Readers who meet the word "thrombopoietin" in a peptide or protein-therapeutics context are usually meeting one of those three threads.

Where It Is Produced and How Levels Are Set

The liver is the dominant source of TPO in adults, with smaller contributions described from the kidney and bone-marrow stromal cells. A distinctive feature of the system is that TPO is produced at a relatively constant rate and its circulating concentration is set largely by consumption: platelets and megakaryocytes express MPL, bind TPO and remove it from the circulation. When the platelet mass falls, less TPO is cleared, free TPO rises, and megakaryopoiesis is stimulated — a sponge-like feedback loop rather than a classical transcriptional thermostat.

That clearance model explains an observation clinicians describe: TPO concentrations are typically high in states of marrow failure, where there are few megakaryocytes to absorb the hormone, but can be near-normal in immune thrombocytopenia, where platelet destruction is peripheral and megakaryocyte mass is preserved. Reviews of thrombopoietin receptor agonists have discussed this distinction when explaining why pharmacological MPL stimulation is used in some low-platelet states and not others (PMID 38261691).

How TPO Signals

TPO binding brings two MPL chains together and activates receptor-associated JAK2, which triggers downstream STAT, MAPK and PI3K/AKT cascades. Researchers assembled a curated network map of thrombopoietin signalling that catalogued the molecules, post-translational modifications and protein–protein interactions reported downstream of MPL activation, providing a reference resource for the pathway (PMID 30039510).

Structural work added geometry to that map. A 2023 study reported the structure of the thrombopoietin–MPL receptor complex and described how the arrangement of the receptor dimer could serve as a blueprint for biasing haematopoietic output — that is, for engineering ligands that engage the same receptor but produce different cellular outcomes (PMID 37633268). This is one of the clearest reasons the hormone matters to protein- and peptide-engineering research: receptor geometry, not just receptor occupancy, appears to shape the signal.

Beyond platelets: stem and progenitor cells

MPL is not restricted to the megakaryocyte lineage. A study in Stem Cell Reports reported that the haematopoietic stem and progenitor cell hierarchy is established by thrombopoietin-driven neonatal haematopoiesis, linking TPO signalling to how the stem cell compartment is organised early in life (PMID 41895275). Loss-of-function models remain a standard way to probe this: researchers described a new mouse model of thrombopoietin deficiency arising from a spontaneous single base pair mutation, adding a genetic tool for studying what happens when the ligand is absent (PMID 41459710).

Conversely, not every route to platelet-like particles requires the hormone. One report described thrombopoietin-independent generation of platelet-like particles from megakaryoblastic cells, which is relevant to laboratory platelet-production systems (PMID 38110522).

How Thrombopoietin Is Measured and Studied

In practice, TPO is studied through several complementary approaches rather than one standard assay:

Measurement also appears in unusual clinical contexts. A case report described a thrombopoietin-producing hepatocellular carcinoma, in which tumour production of the hormone was linked to the patient's platelet picture (PMID 12924502). In comparative medicine, a veterinary study measured interleukin-6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis, examining whether these mediators tracked with elevated platelet counts (PMID 34881459).

Thrombopoietin Receptor Agonists: What Studies Report

Early recombinant thrombopoietin proteins were explored and then largely abandoned, and the field moved to molecules that engage MPL without reproducing the native sequence. A 2007 education-programme review of novel thrombopoietic agents surveyed that transition and the classes of agent then under development (PMID 18024617). Later overviews of thrombopoietin receptor agonists described the agents in clinical use — including the peptibody romiplostim and the small-molecule eltrombopag — and their role in thrombocytopenic conditions (PMID 31643431, PMID 38261691).

Chemotherapy-induced thrombocytopenia (CIT) is where much of the recent clinical literature sits. A Blood Reviews article on optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists reviewed the evidence base and the open questions around patient selection and timing (PMID 37914568). A 2025 British Journal of Haematology review of modern diagnosis and treatment of CIT covered how the condition is defined and worked up alongside treatment options (PMID 40040262). Reported safety considerations discussed in receptor-agonist overviews have included thrombotic events, marrow reticulin changes and rebound thrombocytopenia after discontinuation, and hepatobiliary laboratory abnormalities with some agents (PMID 38261691, PMID 31643431). This page does not describe dosing, because dosing of these prescription agents is a clinical decision documented in product labelling and the reviews themselves.

Why It Matters to Peptide Research Readers

Thrombopoietin is a reference case for a broader idea in peptide and protein science: a receptor can be engaged by something that looks nothing like the native hormone. Romiplostim is a peptide-Fc fusion rather than a TPO analogue, and the structural work on the TPO–MPL complex was explicitly framed as a blueprint for biasing haematopoiesis through engineered ligands (PMID 37633268). Readers encountering TPO in a peptide context are usually encountering receptor pharmacology, not a compound available outside clinical settings.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, laboratory result or treatment. Thrombopoietin receptor agonists are prescription medicines, and the studies summarised here describe research and clinical populations, not general use.

Limitations of the Evidence

• Circulating TPO assays are not standardised across laboratories, which limits comparison of absolute values between studies.
• Much mechanistic work is from animal and cell models, including the deficiency mouse described in PMID 41459710 and the megakaryoblastic cell system in PMID 38110522.
• Reviews of CIT management have noted that optimal patient selection remains unsettled (PMID 37914568).

References

• Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis (Cell, 2023)
• A network map of thrombopoietin signaling (Journal of Cell Communication and Signaling, 2018)
• Hematopoietic stem and progenitor cell hierarchy is established by thrombopoietin-driven neonatal hematopoiesis (Stem Cell Reports, 2026)
• A new mouse model of thrombopoietin deficiency arising from a spontaneous single base pair mutation (Platelets, 2026)
• Thrombopoietin-independent generation of platelet-like particles from megakaryoblastic cells (Scientific Reports, 2023)
• Thrombopoietin Receptor Agonists (2026)
• Thrombopoietin Receptor Agonists (2012)
• Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists (Blood Reviews, 2024)
• Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment (British Journal of Haematology, 2025)
• Novel thrombopoietic agents (Hematology, ASH Education Program, 2007)
• Thrombopoietin-producing hepatocellular carcinoma (Internal Medicine, 2003)
• Interleukin-6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis (Journal of Veterinary Internal Medicine, 2022)